vs
agilon health, inc.（AGL）与MANGOCEUTICALS, INC.（MGRX）财务数据对比。点击上方公司名可切换其他公司
agilon health, inc.的季度营收约是MANGOCEUTICALS, INC.的16633.0倍（$1.6B vs $94.4K）。agilon health, inc.净利率更高（-12.0% vs -2935.1%，领先2923.1%）。agilon health, inc.同比增速更快（3.1% vs -10.3%）。过去两年agilon health, inc.的营收复合增速更高（-1.1% vs -33.6%）
agilon health是一家美国医疗保健企业，主要与基层医疗服务提供者合作，为联邦医疗保险覆盖的老年群体提供价值导向型医疗解决方案，为医生提供行政支持、临床工具及风险管理框架，在提升诊疗效果的同时降低医疗成本，业务覆盖美国20余个州。
MANGOCEUTICALS INC是一家专注男士健康护理的企业，研发销售经科学验证的膳食补充剂、男士护肤及护发产品，主要面向美国市场，通过直营电商平台及精选零售渠道为成年男性提供便捷透明的健康护理解决方案。
AGL vs MGRX — 直观对比
营收规模更大
AGL
是对方的16633.0倍
$94.4K
营收增速更快
AGL
高出13.4%
-10.3%
净利率更高
AGL
高出2923.1%
-2935.1%
两年增速更快
AGL
近两年复合增速
-33.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $94.4K |
| 净利润 | $-188.9M | $-2.8M |
| 毛利率 | — | 50.3% |
| 营业利润率 | -12.3% | -389.7% |
| 净利率 | -12.0% | -2935.1% |
| 营收同比 | 3.1% | -10.3% |
| 净利润同比 | -78.5% | -42.1% |
| 每股收益（稀释后） | — | $0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGLMGRX
| Q4 25 | $1.6B | $94.4K | ||
| Q3 25 | $1.4B | $84.2K | ||
| Q2 25 | $1.4B | $168.1K | ||
| Q1 25 | $1.5B | $109.3K | ||
| Q4 24 | $1.5B | $105.2K | ||
| Q3 24 | $1.5B | $133.4K | ||
| Q2 24 | $1.5B | $163.2K | ||
| Q1 24 | $1.6B | $214.1K |
净利润AGLMGRX
| Q4 25 | $-188.9M | $-2.8M | ||
| Q3 25 | $-110.2M | $-7.6M | ||
| Q2 25 | $-104.4M | $-5.4M | ||
| Q1 25 | $12.1M | $-4.8M | ||
| Q4 24 | $-105.8M | $-1.9M | ||
| Q3 24 | $-117.6M | $-2.0M | ||
| Q2 24 | $-30.7M | $-2.4M | ||
| Q1 24 | $-6.1M | $-2.4M |
毛利率AGLMGRX
| Q4 25 | — | 50.3% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 53.5% | ||
| Q1 25 | — | 56.8% | ||
| Q4 24 | — | 76.1% | ||
| Q3 24 | — | 62.0% | ||
| Q2 24 | — | 42.8% | ||
| Q1 24 | — | 68.8% |
营业利润率AGLMGRX
| Q4 25 | -12.3% | -389.7% | ||
| Q3 25 | -9.1% | -8953.5% | ||
| Q2 25 | -8.3% | -3134.0% | ||
| Q1 25 | -1.4% | -4440.0% | ||
| Q4 24 | -7.1% | -1594.0% | ||
| Q3 24 | -9.2% | -1318.2% | ||
| Q2 24 | -2.9% | -1329.1% | ||
| Q1 24 | -0.4% | -1105.9% |
净利率AGLMGRX
| Q4 25 | -12.0% | -2935.1% | ||
| Q3 25 | -7.7% | -9042.8% | ||
| Q2 25 | -7.5% | -3221.6% | ||
| Q1 25 | 0.8% | -4427.4% | ||
| Q4 24 | -6.9% | -1851.2% | ||
| Q3 24 | -8.1% | -1499.0% | ||
| Q2 24 | -2.1% | -1465.4% | ||
| Q1 24 | -0.4% | -1105.9% |
每股收益（稀释后）AGLMGRX
| Q4 25 | — | $0.38 | ||
| Q3 25 | — | $-0.69 | ||
| Q2 25 | — | $-0.57 | ||
| Q1 25 | — | $-1.29 | ||
| Q4 24 | — | $-0.79 | ||
| Q3 24 | — | $-1.14 | ||
| Q2 24 | — | $-1.37 | ||
| Q1 24 | — | $-1.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $173.7M | $1.5M |
| 总债务越低越好 | $35.0M | — |
| 股东权益账面价值 | $126.7M | $15.2M |
| 总资产 | $1.3B | $16.1M |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资AGLMGRX
| Q4 25 | $173.7M | $1.5M | ||
| Q3 25 | $171.7M | $481.3K | ||
| Q2 25 | $171.4M | $101.0K | ||
| Q1 25 | $136.9M | $76.5K | ||
| Q4 24 | $188.2M | $58.7K | ||
| Q3 24 | $148.2M | $73.9K | ||
| Q2 24 | $109.5M | $490.2K | ||
| Q1 24 | $111.7M | $15.3K |
总债务AGLMGRX
| Q4 25 | $35.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益AGLMGRX
| Q4 25 | $126.7M | $15.2M | ||
| Q3 25 | $306.1M | $15.7M | ||
| Q2 25 | $408.9M | $19.2M | ||
| Q1 25 | $500.3M | $20.3M | ||
| Q4 24 | $471.0M | $13.9M | ||
| Q3 24 | $574.9M | $13.4M | ||
| Q2 24 | $676.6M | $13.8M | ||
| Q1 24 | $689.3M | $-958.4K |
总资产AGLMGRX
| Q4 25 | $1.3B | $16.1M | ||
| Q3 25 | $1.6B | $16.5M | ||
| Q2 25 | $1.7B | $20.8M | ||
| Q1 25 | $1.9B | $21.8M | ||
| Q4 24 | $1.7B | $15.4M | ||
| Q3 24 | $2.1B | $14.8M | ||
| Q2 24 | $2.2B | $15.2M | ||
| Q1 24 | $2.3B | $301.4K |
负债/权益比AGLMGRX
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-20.5M | $-1.1M |
| 自由现金流经营现金流 - 资本支出 | $-23.5M | — |
| 自由现金流率自由现金流/营收 | -1.5% | — |
| 资本支出强度资本支出/营收 | 0.2% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-119.0M | — |
8季度趋势，按日历期对齐
经营现金流AGLMGRX
| Q4 25 | $-20.5M | $-1.1M | ||
| Q3 25 | $-18.2M | $-1.2M | ||
| Q2 25 | $-35.1M | $-1.3M | ||
| Q1 25 | $-32.0M | $-2.3M | ||
| Q4 24 | $16.4M | $-1.1M | ||
| Q3 24 | $-7.7M | $-1.2M | ||
| Q2 24 | $-18.7M | $-1.6M | ||
| Q1 24 | $-47.8M | $-991.1K |
自由现金流AGLMGRX
| Q4 25 | $-23.5M | — | ||
| Q3 25 | $-21.3M | — | ||
| Q2 25 | $-38.3M | — | ||
| Q1 25 | $-35.8M | — | ||
| Q4 24 | $13.2M | — | ||
| Q3 24 | $-11.2M | — | ||
| Q2 24 | $-22.0M | — | ||
| Q1 24 | $-50.9M | — |
自由现金流率AGLMGRX
| Q4 25 | -1.5% | — | ||
| Q3 25 | -1.5% | — | ||
| Q2 25 | -2.7% | — | ||
| Q1 25 | -2.3% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | -0.8% | — | ||
| Q2 24 | -1.5% | — | ||
| Q1 24 | -3.2% | — |
资本支出强度AGLMGRX
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.2% | — |
现金转化率AGLMGRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -2.64× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AGL
| Medical Services | $1.6B | 100% |
| Other Operating | $2.5M | 0% |
MGRX
暂无分部数据
